Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates - Episode 7
Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC
The panel discusses which patients with EGFR-mutant non-small cell lung cancer (NSCLC) are more likely to receive frontline treatment with either osimertinib monotherapy or the combination of osimertinib and chemotherapy, based on individual patient characteristics and preferences.
Video Player is loading.
- In which patients are you likely to choose osimertinib monotherapy vs osimertinib + chemotherapy combination in the frontline setting?In which patients are you likely to choose osimertinib monotherapy vs osimertinib + chemotherapy combination in the frontline setting?
Related Content:
